f Pharmacogenetics of Statin-Induced Myopathy: Genetic Gatekeepers Shaping Precision Therapeutics

References

1. Wehbe Z. Nasser S.A. El-Yazbi A. Nasreddine S. Eid A.H. Estrogen and bisphenol a in hypertension. Curr. Hypertens. Rep. 2020 22 3 23 10.1007/s11906‑020‑1022‑z 32114652
   [Google Scholar]
2. Cardiovascular diseases (CVDs). 2025 Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
3. Fardoun M.M. Matar A. Khachab M. Dakroub A.H. Eid A.H. Cigarette smoke extract induces p38-mediated expression and ROS/rho-mediated translocation of alpha 2C adrenoceptor in human microvascular smooth muscle cells. Prog. Cardiovasc. Dis. 2025 89 119 126 10.1016/j.pcad.2025.01.002 39793863
   [Google Scholar]
4. Sawma T. Shaito A. Najm N. Sidani M. Orekhov A. El-Yazbi A.F. Iratni R. Eid A.H. Role of RhoA and Rho-associated kinase in phenotypic switching of vascular smooth muscle cells: Implications for vascular function. Atherosclerosis 2022 358 12 28 10.1016/j.atherosclerosis.2022.08.012 36049290
   [Google Scholar]
5. Rodriguez F. Maron D.J. Knowles J.W. Virani S.S. Lin S. Heidenreich P.A. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019 4 3 206 213 10.1001/jamacardio.2018.4936 30758506
   [Google Scholar]
6. Ali A.H. Younis N. Abdallah R. Shaer F. Dakroub A. Ayoub M.A. Iratni R. Yassine H.M. Zibara K. Orekhov A. El-Yazbi A.F. Eid A.H. Lipid-lowering therapies for atherosclerosis: Statins, fibrates, ezetimibe and PCSK9 monoclonal antibodies. Curr. Med. Chem. 2021 28 36 7427 7445 10.2174/1875533XMTE03NDEo0 33655822
   [Google Scholar]
7. Ward N.C. Watts G.F. Eckel R.H. Statin toxicity. Circ. Res. 2019 124 2 328 350 10.1161/CIRCRESAHA.118.312782 30653440
   [Google Scholar]
8. Buettner C. Rippberger M.J. Smith J.K. Leveille S.G. Davis R.B. Mittleman M.A. Statin use and musculoskeletal pain among adults with and without arthritis. Am. J. Med. 2012 125 2 176 182 10.1016/j.amjmed.2011.08.007 22269621
   [Google Scholar]
9. Cheeley M.K. Saseen J.J. Agarwala A. Ravilla S. Ciffone N. Jacobson T.A. Dixon D.L. Maki K.C. NLA scientific statement on statin intolerance: A new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J. Clin. Lipidol. 2022 16 4 361 375 10.1016/j.jacl.2022.05.068 35718660
   [Google Scholar]
10. Link E. Parish S. Armitage J. Bowman L. Heath S. Matsuda F. Gut I. Lathrop M. Collins R. SLCO1B1 variants and statin-induced myopathy--A genomewide study. N. Engl. J. Med. 2008 359 8 789 799 10.1056/NEJMoa0801936 18650507
    [Google Scholar]
11. Ferrari M. Guasti L. Maresca A. Mirabile M. Contini S. Grandi A.M. Marino F. Cosentino M. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur. J. Clin. Pharmacol. 2014 70 5 539 547 10.1007/s00228‑014‑1661‑6 24595600
    [Google Scholar]
12. Kitzmiller J. Mikulik E. Dauki A. Mukherjee C. Luzum J. Pharmacogenomics of statins: Understanding susceptibility to adverse effects. Pharm. Genomics Pers. Med. 2016 9 97 106 10.2147/PGPM.S86013 27757045
    [Google Scholar]
13. Kee P.S. Chin P.K.L. Kennedy M.A. Maggo S.D.S. Pharmacogenetics of statin-induced myotoxicity. Front. Genet. 2020 11 575678 10.3389/fgene.2020.575678 33193687
    [Google Scholar]
14. Sridharan K. Sivaramakrishnan G. Genetic determinants of statin-induced myopathy: A network meta-analysis of observational studies. Curr. Rev. Clin. Exp. Pharmacol. 2026 21 1 75 91
    [Google Scholar]
15. Liu M. Fan F. Zhang Y. Li J. The association of GATM polymorphism with statin-induced myopathy: A systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 2021 77 3 349 357 10.1007/s00228‑020‑03019‑3 33051696
    [Google Scholar]
16. Kitzmiller J.P. Luzum J.A. Baldassarre D. Krauss R.M. Medina M.W. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenet. Genomics 2014 24 10 486 491 10.1097/FPC.0000000000000079 25051018
    [Google Scholar]
17. Yee J. Kim H. Heo Y. Yoon H.Y. Song G. Gwak H.S. Association between CYP3A5 polymorphism and statin-induced adverse events: A systemic review and meta-analysis. J. Pers. Med. 2021 11 7 677 10.3390/jpm11070677 34357144
    [Google Scholar]
18. Vassy J.L. Gaziano J.M. Green R.C. Ferguson R.E. Advani S. Miller S.J. Chun S. Hage A.K. Seo S.J. Majahalme N. MacMullen L. Zimolzak A.J. Brunette C.A. Effect of pharmacogenetic testing for statin myopathy risk vs usual care on blood cholesterol. JAMA Netw. Open 2020 3 12 e2027092 10.1001/jamanetworkopen.2020.27092 33270123
    [Google Scholar]
19. Peyser B. Perry E.P. Singh K. Gill R.D. Mehan M.R. Haga S.B. Musty M.D. Milazzo N.A. Savard D. Li Y.J. Trujilio G. Voora D. Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings. Circ. Genom. Precis. Med. 2018 11 9 e002228 10.1161/CIRCGEN.118.002228 30354330
    [Google Scholar]
20. Cooper-DeHoff R.M. Niemi M. Ramsey L.B. Luzum J.A. Tarkiainen E.K. Straka R.J. Gong L. Tuteja S. Wilke R.A. Wadelius M. Larson E.A. Roden D.M. Klein T.E. Yee S.W. Krauss R.M. Turner R.M. Palaniappan L. Gaedigk A. Giacomini K.M. Caudle K.E. Voora D. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin‐associated musculoskeletal symptoms. Clin. Pharmacol. Ther. 2022 111 5 1007 1021 10.1002/cpt.2557 35152405
    [Google Scholar]
21. Wilke R.A. Ramsey L.B. Johnson S.G. Maxwell W.D. McLeod H.L. Voora D. Krauss R.M. Roden D.M. Feng Q. Cooper-DeHoff R.M. Gong L. Klein T.E. Wadelius M. Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 2012 92 1 112 117 10.1038/clpt.2012.57 22617227
    [Google Scholar]